The malignant phenotype in breast cancer is driven by eIf4A1-mediated changes in the translational landscape

Cell Death and Disease

Volumn 6, Issue 1, 2015, Pages

  Modelska, A ^a   Turro, E ^a,b   Russell, R ^a   Beaton, J ^a   Sbarrato, T ^c   Spriggs, K ^d   Miller, J ^a   Graf S ^a,b,e   Provenzano, E ^f   Blows, F ^g   Pharoah, P ^f,g   Caldas, C ^a,f   Le Quesne, J ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MRC TOXICOLOGY UNIT   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE QUADRUPLEX; INITIATION FACTOR 4A; INITIATION FACTOR 4A1; INITIATION FACTOR 4B; INITIATION FACTOR 4E; MESSENGER RNA; UNCLASSIFIED DRUG; 5' UNTRANSLATED REGION; APOPTOSIS REGULATORY PROTEIN; DNA HELICASE; EIF-4B; ESTROGEN RECEPTOR; INITIATION FACTOR; MICRORNA; PDCD4 PROTEIN, HUMAN; RNA BINDING PROTEIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MCF 7 CELL LINE; ONCOGENE; OUTCOME ASSESSMENT; PHENOTYPE; POLYSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; TUMOR VOLUME; UPREGULATION; APOPTOSIS; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; DNA REPAIR; ENDOPLASMIC RETICULUM; FEMALE; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROTEIN SYNTHESIS; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR GENE;

5' UNTRANSLATED REGIONS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BASE SEQUENCE; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA HELICASES; DNA REPAIR; ENDOPLASMIC RETICULUM; EUKARYOTIC INITIATION FACTOR-4A; EUKARYOTIC INITIATION FACTORS; FEMALE; GENES, NEOPLASM; HUMANS; KAPLAN-MEIER ESTIMATE; MICRORNAS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; PROTEIN BIOSYNTHESIS; RECEPTORS, ESTROGEN; RNA, MESSENGER; RNA-BINDING PROTEINS; TREATMENT OUTCOME;

EID: 84925468028     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.542     Document Type: Article

References (52)

1. Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet 2012; 13: 227-232.
2. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J et al. Global quantification of mammalian gene expression control. Nature 2011; 473: 337-342.
3. Jackson RJ, Hellen CU, Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol 2010; 11: 113-127.
4. Hinnebusch AG, Lorsch JR. The mechanism of eukaryotic translation initiation: new insights and challenges. Cold Spring Harb Perspect Biol 2012; 4: pii: a011544.
5. Shahbazian D, Parsyan A, Petroulakis E, Hershey J, Sonenberg N. eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways. Cell Cycle 2010; 9: 4106-4109.
6. Feoktistova K, Tuvshintogs E, Do A, Fraser CS. Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity. Proc Natl Acad Sci USA 2013; 110: 13339-13344.
7. Lankat-Buttgereit B, Goke R. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biol Cell 2009; 101: 309-317.
8. Meijer HA, Kong YW, Lu WT, Wilczynska A, Spriggs RV, Robinson SW et al. Translational repression and eIF4A2 activity are critical for microRNA-mediated gene regulation. Science 2013; 340: 82-85.
9. Babendure JR, Babendure JL, Ding JH, Tsien RY. Control of mammalian translation by mRNA structure near caps. RNA 2006; 12: 851-861.
10. Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature 1990; 345: 544-547.
11. Coleman LJ, Peter MB, Teall TJ, Brannan RA, Hanby AM, Honarpisheh H et al. Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer 2009; 100: 1393-1399.
12. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004; 23: 3189-3199.
13. Shahbazian D, Parsyan A, Petroulakis E, Topisirovic I, Martineau Y, Gibbs BF et al. Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. Mol Cell Biol 2010; 30: 1478-1485.
14. Horvilleur E, Sbarrato T, Hill K, Spriggs RV, Screen M, Goodrem PJ et al. A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma. Leukemia 2014; 28: 1092-1102.
15. Jansen AP, Camalier CE, Colburn NH. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res 2005; 65: 6034-6041.
16. Meric-Bernstam F, Chen H, Akcakanat A, Do KA, Lluch A, Hennessy BT et al. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res 2012; 14: R138.
17. Wen YH, Shi X, Chiriboga L, Matsahashi S, Yee H, Afonja O. Alterations in the expression of PDCD4 in ductal carcinoma of the breast. Oncol Rep 2007; 18: 1387-1393.
18. Jin C, Rajabi H, Rodrigo CM, Porco Jr JA, Kufe D. Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein. Oncogene 2013; 32: 2179-2188.
19. Tsumuraya T, Ishikawa C, Machijima Y, Nakachi S, Senba M, Tanaka J et al. Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. Biochem Pharmacol 2011; 81: 713-722.
20. Cencic R, Robert F, Galicia-Vazquez G, Malina A, Ravindar K, Somaiah R et al. Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A. Blood Cancer J 2013; 3: e128.
21. Cencic R, Carrier M, Galicia-Vazquez G, Bordeleau ME, Sukarieh R, Bourdeau A et al. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS One 2009; 4: e5223.
22. Bordeleau ME, Mori A, Oberer M, Lindqvist L, Chard LS, Higa T et al. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat Chem Biol 2006; 2: 213-220.
23. Bohm M, Sawicka K, Siebrasse JP, Brehmer-Fastnacht A, Peters R, Klempnauer KH. The transformation suppressor protein Pdcd4 shuttles between nucleus and cytoplasm and binds RNA. Oncogene 2003; 22: 4905-4910.
24. Turro E, Su SY, Goncalves A, Coin LJ, Richardson S, Lewin A. Haplotype and isoform specific expression estimation using multi-mapping RNA-seq reads. Genome Biol 2011; 12: R13.
25. Turro E, Astle WJ, Tavare S. Flexible analysis of RNA-seq data using mixed effects models. Bioinformatics 2014; 30: 180-188.
26. Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009; 69: 3955-3962.
27. Bailey TL, Elkan C. Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc Int Conf Intell Syst Mol Biol 1994; 2: 28-36.
28. Wolfe AL, Singh K, Zhong Y, Drewe P, Rajasekhar VK, Sanghvi VR et al. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature 2014; 513: 65-70.
29. Liu H, Matsugami A, Katahira M, Uesugi S. A dimeric RNA quadruplex architecture comprised of two G:G(:A):G:G(:A) hexads, G:G:G:G tetrads and UUUU loops. J Mol Biol 2002; 322: 955-970.
30. Keller A, Backes C, Al-Awadhi M, Gerasch A, Kuntzer J, Kohlbacher O et al. GeneTrailExpress: a web-based pipeline for the statistical evaluation of microarray experiments. BMC Bioinformatics 2008; 9: 552.
31. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
32. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007; 8: R157.
33. Ali HR, Dawson SJ, Blows FM, Provenzano E, Pharoah PD, Caldas C. Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Res 2011; 13: R118.
34. Ali HR, Dawson SJ, Blows FM, Provenzano E, Pharoah PD, Caldas C. Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer. Br J Cancer 2012; 106: 1798-1806.
35. Yang HS, Matthews CP, Clair T, Wang Q, Baker AR, Li CC et al. Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion. Mol Cell Biol 2006; 26: 1297-1306.
36. Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature 2014; 513: 105-109.
37. Lesueur F, Pharoah PD, Laing S, Ahmed S, Jordan C, Smith PL et al. Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer. Hum Mol Genet 2005; 14: 2349-2356.
38. Le Quesne JP, Jones J, Warren J, Dawson SJ, Ali HR, Bardwell H et al. Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue. J Pathol 2012; 227: 306-314.
39. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010; 7: e1000279.
40. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97: 1180-1184.
41. Azzato EM, Greenberg D, Shah M, Blows F, Driver KE, Caporaso NE et al. Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? Br J Cancer 2009; 100: 1806-1811.
42. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
43. Dunning MJ, Smith ML, Ritchie ME, Tavare S. beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 2007; 23: 2183-2184.
44. Cairns JM, Dunning MJ, Ritchie ME, Russell R, Lynch AG. BASH: a tool for managing BeadArray spatial artefacts. Bioinformatics 2008; 24: 2921-2922.
45. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article 3.
46. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 1995; 57: 289-300.
47. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 2009; 10: R25.
48. Flicek P, Amode MR, Barrell D, Beal K, Brent S, Chen Y et al. Ensembl 2011. Nucleic Acids Res 2011; 39: D800-D806.
49. Hofacker IL, Stadler PF. Memory efficient folding algorithms for circular RNA secondary structures. Bioinformatics 2006; 22: 1172-1176.
50. Bailey TL, Boden M, Buske FA, Frith M, Grant CE, Clementi L et al. MEME SUITE: tools for motif discovery and searching. Nucleic Acids Res 2009; 37: W202-W208.
51. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J et al. PGC-1alpharesponsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267-273.
52. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.